Estimates of the lifetime costs of breast cancer treatment in Canada

European Journal of Cancer

Volumn 36, Issue 6, 2000, Pages 724-735

  Will, B P ^a   Berthelot, J M ^a   Le Petit, C ^a   Tomiak, E M ^b   Verma, S ^b   Evans, W K ^b  

^a Health Analysis and Measurement Group   (Canada)

^b CANCER CARE ONTARIO   (Canada)

Author keywords

Breast cancer; Direct care costs; Disease costing; Microsimulation model

Indexed keywords

ARTICLE; BREAST CANCER; CANADA; CANCER REGISTRY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEALTH CARE COST; HUMAN; LIFESPAN; MEDICAL SERVICE; PRIORITY JOURNAL; SIMULATION; STATISTICS;

ADULT; ALGORITHMS; BREAST NEOPLASMS; CANADA; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HUMANS; LONG-TERM CARE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TERMINAL CARE;

EID: 0034112462     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00340-8     Document Type: Article

References (39)

1. National Cancer Institute of Canada. Canadian Cancer Statistics 1995. Toronto, Canada, 1995.
2. Wolfson M.C. POHEM - a framework for understanding and modelling the health of human populations. World Health Statist. Quart. 47:1994;157-176.
3. Will B.P., Berthelot J.-M., Houle C., Verma S., Tomiak E., Evans W.K. A model for estimating the costs and burdens of breast cancer diagnosis and treatment in Canada. Health Rep. 5:1993;399-408.
4. Drummond M.F. Cost-of-illness studies. a major headache PharmaEconomics. 2:1992;1-4.
5. Will B.P., Le Petit C., Berthelot J.-M., Tomiak E.M., Verma S., Evans W.K. Diagnostic and therapeutic approaches for non-metastatic breast cancer in Canada, and their associated costs. Br. J. Cancer. 79:1999;1428-1436.
6. Sobin LH, Wittekind Ch, eds. UICC International Union Against Cancer. TNM Classification of Malignant Tumours, 5th edn. New York, Wiley-Liss, 1997.
7. Statistics Canada. National Person-oriented Database of Hospital Discharges, 1993-1994.
8. Tomiak E.M., Diverty B., Verma S.et al. Follow-up practices for patients with early stage breast cancer. a survey of Canadian oncologists Cancer Prev. and Control. 2:1998;62-71.
9. Aisner J, Moossa AR, Schimpff SC, Robson MC, eds. Management of advanced disseminated breast cancer. Comprehensive Textbook of Oncology, 2nd edn. Balimore, Williams & Wilkins, 1991, 85, 836-844.
10. Hayes D.F., Henderson I.C., Shapiro C.L. Treatment of metastatic breast cancer. present and future prospects Semin. Oncol. 22(Suppl. 5):1995;5-19.
11. Hillner B.E. Economic and cost-effectiveness issues in breast cancer treatment. Semin. Oncol. 23(Suppl. 2):1996;98-104.
12. Hortobagyi G.N. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer. 74(Suppl.):1994;416-423.
13. Leonard R.C.F., Rodger A., Dixon J.M. Metastatic breast cancer. Br. Med. J. 309:1994;1501-1504.
14. Quiet C.A., Ferguson D.J., Weichselbaum R.R., Hellman S. Natural history of node-negative breast cancer. a study of 826 patients with long-term follow-up J. Clin. Oncol. 13:1995;1144-1151.
15. Seidman A.D. Chemotherapy for advanced breast cancer. a current perspective Semin. Oncol. 23(Suppl. 2):1996;55-59.
16. Vandenberg T.A. New developments in chemotherapy for metastatic breast cancer. Anticancer Drugs. 5:1994;251-259.
17. Verma S. Metastatic breast cancer. deciding on treatment Contemporary Oncol. 4:1994;14.
18. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In De Vita VT, Hellman S, Rosenberg SA. eds. Cancer: Principles & Practice of Oncology, 4th edn., Philadelphia, J.B. Lippincott, 1993, 1264-1332.
19. Sloan J, Nemecek A. Experiences in Constructing Cancer Patient Trajectories Through the Manitoba Health Care System. Final report to the Manitoba Medical Services Foundation, July 1995.
20. Earle C., Coyle D., Smith A., Agboola O., Evans W.K. The cost of radiotherapy at an Ontario regional cancer centre. Crit. Rev. Oncol./Hematol. 32:1999;87-93.
21. Berthelot J-M, Le Petit C, Flanagan W. Use of longitudinal data in health policy simulation models. In 1997 Proceedings of the Government Statistics Section. American Statistical Association, 1997, 120-129.
22. SAS/STAT User's Guide, Version 6, 4th edn, Volume 2.
23. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., Russell L.B. Recommendations of the panel on cost-effectiveness in health and medicine. J. Am. Med. Assoc. 276:1996;1253-1258.
24. Canadian Coordinating Office for Health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals: Canada, 2nd edn. November 1997.
25. Ontario Case Cost Project (OCCP). Special Retrieval from April 1993 to March 1995 database of 13 Ontario hospitals.
26. Baker M.S., Kessler L.G., Urban N., Smucker R.C. Estimating the treatment costs of breast and lung cancer. Med. Care. 29:1991;40-49.
27. Riley G.F., Potosky A.L., Lubitz J.D., Kessler L.G. Medicare payments from diagnosis to death for elderly patients by stage at diagnosis. Med. Care. 33:1995;828-841.
28. Taplin S.H., Barlow W., Urban N.et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J. Natl. Cancer Inst. 87:1995;417-426.
29. Wolstenholme J.L., Smith S.J., Whynes D.K. The costs of treating breast cancer in the United Kingdom. implications for screening Int. J. Technol. Assess. Health Care. 14:1998;277-289.
30. Organization for Economic Co-operation and Development (OECD) Health Data 3.6 version. 2, rue Andre Pascal, 75775, Paris, CEDEX 16, France.
31. Hurley S.F., Huggins R.M., Snyder R.D., Bishop J.F. The cost of breast cancer recurrences. Br. J. Cancer. 65:1992;449-455.
32. Butler J.R., Furnival C.M., Hart R.F. The costs of treating breast cancer in Australia and the implications for breast cancer screening. Aust. N. Z. J. Surg. 65:1995;485-491.
33. Geddes M., Carli S., Ercolanelli M., Forno G., Capelli M., Barchielli A. Colorectal, lung, and breast cancer care during the three years following the diagnosis. a population-based study Tumori. 82:1996;210-214.
34. Richards M.A., Braysher S., Gregory W.M., Rubens R.D. Advanced breast cancer. use of resources and cost implications Br. J. Cancer. 67:1993;856-860.
35. Hillner B.E. Financial costs, benefits, and patient risk preferences in node-negative breast cancer. insights from a decision analysis model Recent Results Cancer Res. 127:1993;277-284.
36. Koopmanschap M.A., Rutten F.F.H. Indirect costs in economics studies. confronting the confusion PharmacoEconomics. 4:1993;446-454.
37. Evans WK, Le Petit C, Will BP, et al. Strategies to Reduce the Costs of Care for Breast Cancer in Canada. Oral presentation - International Society for Technology Assessment in Health Care - Ottawa, June 1998.
38. Will BP, Berthelot J-M, Houle C, Tomiak EM, Verma S, Evans WK. The Economic Impact of Locoregional Radiotherapy (LRRT) on All Post-surgical Stage II Breast Cancer Patients in Canada. Poster presentation - International Society for Technology Assessment in Health Care - Ottawa, June 1998.
39. Logan D, Will BP, Berthelot J-M, et al. Economic and health impacts of administering preventative tamoxifen to women at high risk of breast cancer in Canada. Oral presentation - American Society of Clinical Oncology annual meeting, Atlanta, Georgia, USA, May 1999. Proc Am Soc Clin Oncol 1999, 18, abstract 1605.